The latest headline-filling case of NHS rationing emerges today, with news that another new cancer drug will be unavailable to patients in the United Kingdom.
This time it's Nexavar, which can extend life for up to 6 months for people with liver cancer.
The announcement comes just weeks after the last of a long string of studies to show up the UK's quite abysmal cancer survival rates. The UK's largely government-owned, -funded and -run health service constantly falls behind other systems which utilise private providers and offer a greater variety of choice.
Meanwhile, on a more optimistic note, the Cato Institute have released an interesting paper on Why America Leads the World in Medical Innovation. Definitely worth a peruse.
Unless, of course, your cancer is being 'treated' by the UK's state monopoly, in which case such innovative drugs will be considered "not cost effective" enough to keep you breathing.